The overexpression of SPRR1B in bronchial epithelium is a marker for early metaplastic changes and the loss of its expression is associated with an irreversible malignant transformation. In the present study, we have used a model system consisting of normal and malignant bronchial epithelial (BE) cells to elucidate the dierential transcriptional control of SPRR1B. SPRR1B expression is either detectable or PMA (phorbol 13-myristate 12-acetate) -inducible in several malignant BE cells including squamous, adeno, small and large cell carcinomas. Loss of SPRR1B expression is correlated well with the lack of strong in vivo protein-DNA interactions at the 7152 bp promoter, which contains two functional TRE sites. Even though the basal level AP-1 protein DNA binding pattern is dierent between normal and malignant cells, PMA signi®cantly enhances Jun and Fos binding to the consensus TRE site in both cell types. Intriguingly, the composition of AP-1 protein binding to the 7152 to 786 bp SPRR1B promoter is quite dierent. In untreated cells, SPRR1B promoter is predominantly occupied by JunD and Fra2. PMA signi®cantly induced binding of JunB and Fra1 in normal cells, while JunB and Fra2 bound to TREs in the malignant cells. Overexpression of fra1 in malignant cells signi®cantly enhanced SPRR1B promoter activity. In contrast, overexpression of fra2, but not fra1, strongly reduced both basal and PMA-inducible promoter activities in normal cells. Together, these results indicate that either temporal expression and/or dierential activation of AP-1 proteins, especially Fra1 and Fra2, might contribute to the dysregulation of terminal dierentiation marker, SPRR1B, expression in various BE cells. Oncogene (2001) 20, 634 ± 644.
Introduction
Lung cancer is one of the most common malignancies around the world and currently is the leading cause of cancer death in the United States. Epidemiological studies have indicated that smoking is one of the major causes of human cancers, particularly of malignancies in the lung. Airway epithelium, which plays an important role in pulmonary defense, is the primary target of damage caused by tobacco smoke that results in several morphological changes associated with squamous cell metaplasia (Basbaum and Jany, 1990; Pfeifer et al., 1989) . Squamous cell dierentiation is a multi-step process consisting of an initial stage, in which cells become committed to terminal dierentiation, followed by the expression of corni®ed envelope (CE, squamous phenotype) precursor proteins and ®nally corni®cation (Jetten, 1989; Pfeifer et al., 1989) . It has been suggested that squamous metaplasia and dysplasia play an important role in bronchial epithelial (BE) cell transformation and that pre-neoplastic cells have a clonal growth advantage over normal cells that may lead to bronchial carcinogenesis. However, the exact molecular mechanisms regulating the induction of squamous dierentiation and bronchial carcinogenesis are not clearly understood.
Recently, several studies have demonstrated SPRR1B (also called corni®n) to be an early biomarker associated with squamous cell dierentiation of airway epithelium (Tesfaigzi and Carlson, 1999) . In contrast to squamous tissues, in vivo airway epithelium normally does not express any signi®cant level of SPRR1B gene products. However, a rapid induction of this gene occurs immediately after epithelial injury caused by a variety of agents, such as phorbol 13-myristate 12-acetate (PMA), carcinogens and tobacco smoke, which promote airway squamous cell metaplasia (Tesfaigzi and Carlson, 1999) . SPRR1B belongs to a SPRR multi-gene family consisting of two SPRR1 genes (1A and 1B), seven SPRR2 genes (2A-2F) and one SPRR3 gene. SPRRs are crosslinked either to themselves and/ or to other CE precursor proteins, such as loricrin and play an important role in modulation of the epithelial barrier function of squamous tissues, depending upon their physical requirements and function (Steinert et al., 1998) . Recently, we have demonstrated the actual participation of SPRR1B in BE cell corni®cation (Deng et al., 2000) . Because of its expression in nonsquamous epithelial cells (e.g., CHO cells) and its antigen localization in the nuclei, it is generally believed that SPRR1B might play a regulatory role in cell growth and dierentiation (Tesfaigzi and Carlson, 1999) .
The 5'-¯anking region of SPRRs contains functional cis-acting elements including a TATA box, Ets binding site, CACCC/GTGGG or Sp1-like binding site, Oct-11 binding site, IFN-responsive elements, and TRE sites. SPRR family members are dierentially regulated by PMA, Ca 2+ , cytokines, and UV irradiation indicating that their transcription is modulated by dierent signaling pathways depending on cellular and promoter context (Tesfaigzi and Carlson, 1999) . For example, it was shown that four dierent types of transcription factors act in concert in an interdependent manner to regulate expression of SPRR2AB in keratinocytes (Fischer et al., 1996) . The expression and regulation of SPRRs in BE cells is not clearly understood. Previously, we have demonstrated that inducible expression of SPRR1 (now called SPRR1B) by PMA is mainly regulated by the 7152 bp 5'-¯anking region containing two TRE sites located at the nucleotide position of 7141 and 7111. Recently, Sark et al. demonstrated that SPRR1A contains a TATA box, Ets, and TRE site, in identical locations as found in the SPRR1B promoter. Both Ets and TRE sites are critical for PMA-stimulated SPRR1A gene regulation in human keratinocytes (Sark et al., 1998) . It is interesting, however, to note that SPRR1A contains one TRE site, located at nucleotide 7111, indicating a potential dierence in its transcriptional regulation as compared to SPRR1B (Reddy et al., 1995; Sark et al., 1998) . PMA-stimulates SPRR1A mRNA levels and promoter activity in human BE cells (data not shown), however, it is not clear whether the molecular mechanisms (transcription factors and/or signal transduction pathways) regulating 1A and 1B expression in keratinocytes and BE cells are the same or distinct to each cell type.
Several studies have demonstrated the loss of expression of SPRR family members in dierent types of malignant epithelial cells as compared to expression levels in their normal counterparts (Tesfaigzi and Carlson, 1999) . Previously, we have demonstrated a decreased level of SPRR1B expression in bronchial epithelial cells when the cells have adopted malignant features (Lau et al., 2000; Reddy et al., 1995) . In another study, loss of SPRR1B expression, but not of other CE precursors such as involucrin and loricrin, has been reported in 12 of 12 malignant human BE cells (DeMuth et al., 1998) . Several additional studies have shown loss of expression of SPRR family members in several skin squamous carcinoma cells (Fujimoto et al., 1993; Lohman et al., 1997; Yaar et al., 1995) . The expression of SPRR3 was not detectable in esophageal squamous cell carcinomas as compared to its expression in normal cells (Abraham et al., 1996) . Similarly, SPRR1B expression was seen in normal breast cells, but was undetected in several breast cancer cells (Anisowicz et al., 1999) . Although several studies showed the loss of expression of SPRR family members in various malignant cells, the molecular mechanisms governing this process are not clearly understood.
To gain additional insight into the development of airway squamous cell metaplasia and bronchial carcinogenesis, we have studied the transcriptional mechanisms involved in dysregulation of SPRR1B expression in malignant BE cells. By in vivo footprinting, transient transfections, and electrophoretic mobility shift analysis, we demonstrate that dierential expression and PMA-inducible regulation of SPRR1B in BE cells is mainly mediated by a 7152 to +12 bp promoter region containing two functional TRE (AP-1) sites. Interestingly, the pattern of AP-1 protein binding at the functional TRE sites of the SPRR1B promoter is dierent between normal and malignant BE cells. These results indicate that alteration(s) in the composition of AP-1 protein DNA binding might play an important role in dysregulation of SPRR1B expression in various BE cells.
Results

Differential regulation of SPRR1B expression in normal, immortalized and malignant BE cells
To demonstrate the dierential induction of SPRR1B, we studied its expression patterns in a model system consisting of normal and bronchial carcinoma cells. The cell culture system contained primary cultured tracheobronchial epithelial cells (PBE), immortalized normal BE cells, HBE1 and BEAS-2B (clone S-6), and various malignant (squamous, adeno, large and small cell carcinoma) BE cell lines. Cells were treated either with DMSO (vehicle) or 100 ng/ml PMA (5 ng/ml for PBE cells) for dierent time periods as indicated. Total RNA was isolated and Northern blot analysis was carried out as described in Materials and methods. As shown in Figure 1a , SPRR1B mRNA levels are highly abundant in PBE cells (data not shown), while HBE1 cells showed a moderate level (lane 11), and BEAS-2B (clone S-6) cells showed very low levels (lane 9). PMA signi®cantly enhanced SPRR1B message levels in PBE (data not shown), HBE1 (lane 12 and BEAS-2B (lane 10) cells. Moreover, the pattern of SPRR1B expression in both basal and PMA-stimulated cells was also re¯ected at the protein level. As shown in Figure 1b , HBE1 cells displayed high basal level of SPRR1B as compared to BEAS-2B cells (compare lane 1 with lane 3). PMA eectively enhanced the protein levels in both HBE1 and BEAS-2B cells. In contrast, SPRR1B mRNA levels are either detectable or PMA-inducible in various malignant BE cell lines including lung adenocarcinoma (A549), bronchioloalveolar cell carcinoma (H358), squamous cell carcinoma (H520), and lung large cell carcinoma (H661) (Figure 1a , lanes 1 ± 8). SPRR1B antigen was also undetectable in both control and PMA-treated A549 and H358 cells (Figure 1b, lanes 5 ± 8) .
In order to distinguish SPRR1B expression from its counterpart SPRR1A, we have performed a semiquantitative RT ± PCR analysis using sequence speci®c primers as previously described (Sark et al., 1998) . A good corroboration was observed between the results of both Northern blot and RT ± PCR analysis. Northern blot and RT ± PCR analyses were unable to detect SPRR1B message levels in either untreated or PMA treated A549 (Figure 2a (DeMuth et al., 1998; Lau et al., 2000; Reddy et al., 1995) . It should be pointed out that PMA also signi®cantly induces the expression of SPRR1A in HBE1 and BEAS-2B but not in A549 BE cells in a manner similar to that of SPRR1B (data not shown).
In vivo footprinting analysis of SPRR1B promoter in malignant BE cells Previously, we have demonstrated that both basal and PMA-enhanced transcriptional regulation of SPRR1B in normal BE cells is mainly mediated by a 7152 to +12 bp promoter region that contains two functional TRE sites (Reddy et al., 1995) . To further understand the nature of dysregulation of SPRR1B in malignant BE cells, the protein-DNA interactions at the SPRR1B promoter region in intact cells were mapped at single nucleotide resolution by genomic sequencing method using the appropriate primers (see Figure 3a) as previously described (Reddy et al., 1995) . In vivo footprinting data of the coding strand between 7165 to 799 bp region of the SPRR1B promoter is displayed in Figure 3b . Lanes 1 and 2 represent the naked DNA (N) controls in which protein-free genomic DNA was treated with dimethyl sulfate (DMS) and subjected to piperidine treatment. Cleaved DNA fragments were ampli®ed simultaneously along with in vivo DMS-treated samples by LM-PCR as described in Materials and methods. Both primary cultured BE (PBE, lane 3) and HBE1 (lane 4) cells displayed strong footprints at the 7143 to 786 bp promoter. The 7140 G residue of the 5'-TRE motif was partially protected, while the¯anking 7143 G residue showed hyperreactivity. The 7110 G residue of the 3'-TRE-like site was also partially protected. Other protections include the G residues that are part of the GTGGG (7131 to 7127) and ETS-like (7123 to 7116) motifs located between the two TRE-sites. On the contrary, malignant H358 (lane 5) and A549 (lane 6) cells showed very weak footprints as compared to normal BE cells. Moreover, PMA treatment did not change the footprinting pattern very signi®cantly in either normal (Reddy et al., 1995) or malignant BE cell lines (data not shown). These results indicate that the 7142 to 786 bp promoter containing 5'-TRE, GT/ CAC, ETS-like, and 3'-TRE sites plays an important role in dierential regulation of SPRR1B expression in normal and malignant cell lines.
Loss of SPRR1B expression in malignant BE cells is regulated mainly at the transcription level
In order to address whether the weak in vivo footprints observed in malignant cells are also re¯ected at the transcriptional level, both normal and malignant cells were transiently transfected with 152-SPRR1B-CAT chimeric construct. This construct contains the 7152 to +12 bp SPRR1B promoter linked to a CAT reporter gene (Reddy et al., 1995) . To normalize the variation in the transfection eciencies between dierent cell-types, cells were co-transfected with pCMV-b-gal along with SPRR1B promoter construct. CAT activity was expressed as CAT units/b-gal units. CAT gene expression driven by the SPRR1B promoter in the presence (®lled bars) or absence of PMA (open bars) was analysed by ELISA method. As illustrated in Figure 4 , primary cultured human BE cells and Cellular extracts from untreated and PMA-treated BE cells were isolated in keratin extraction buer and quantitated. An equal amount of protein was separated and Western blot analysis was performed using SPRR1B antibodies as described in Materials and methods
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keratinocytes displayed high basal level promoter activity followed by moderate levels in immortalized HBE1 (data not shown) and BEAS-2B cell lines. Furthermore, PMA signi®cantly stimulated basal level promoter activity. In contrast, malignant A549, A431, A172 and Caco-2 cell lines displayed very low levels of both basal and PMA-stimulated promoter activities as compared to normal cells. Malignant cells displayed at least a 10 ± 15-fold decrease in SPRR1B promoter driven CAT expression as compared to normal cells. Together, both in vivo footprinting and transfection studies suggest that cis-acting elements located between Figure 2 PMA inducible expression of SPRR1B in normal but not malignant BE cells. Cells were treated with PMA for indicated periods and total RNA was isolated. (a) Total RNA was isolated, and Northern blot analysis was performed as in Figure 1a . (b) To distinguish SPRR1B expression from its counterpart SPRR1A, RT ± PCR analysis was performed using sequence speci®c primers as described in Materials and methods. The number of cycles (35 for SPRR1B and 28 for actb) was chosen to ensure that the ampli®cation product did not reach a plateau level. The ampli®ed cDNA fragments were separated on a 1.2% agarose gel containing ethidium bromide, and photographed using the Gel Doc 2000 System (Bio-Rad Lab, CA, USA) 
Band shift profiles of AP-1 proteins in normal and malignant BE cells
The present data indicate that malignant cells exhibit weaker in vivo DNA-protein interactions and lower levels of promoter activity as compared to normal cells. We therefore examined whether the pattern of AP-1 protein DNA binding is dierent between these cell types. Nuclear extracts from untreated and PMAtreated HBE1, BEAS-2B and A549 cells were isolated and the AP-1 DNA binding was analysed using 32 Plabeled consensus AP-1 site as described in Materials and methods. The band shift pro®les of untreated and PMA-treated HBE1, BEAS-2B, and A549 cell nuclear extracts are shown in Figure 5 . The basal level AP-1 protein DNA binding is somewhat similar between BEAS-2B and A549 cells while HBE1 cells displayed a slightly higher level. However, treatment of cells with PMA signi®cantly enhanced AP-1 protein binding in all three cell types. We next examined whether the composition of AP-1 protein DNA binding is dierent between these cell types by band supershift analysis using antibodies speci®c for the individual Jun (Figure 5d, lanes 1 ± 7) , while PMA-treatment signi®cantly enhanced c-Jun, JunB, and Fra1 (Figure 5d, lanes 8 ± 14) . Intriguingly, PMA moderately enhanced Fra1 binding, but not as profoundly as that seen with the HBE1 and BEAS-2B cell nuclear extracts. Together, these results indicate that even though there is a signi®cant variation in the DNA binding activity of AP-1 family members between normal and malignant BE cells, PMA strongly enhanced Jun and Fos protein DNA binding in both cells.
Differential binding of AP-1 proteins to the SPRR1B promoter between normal and malignant BE cells
We next analysed nuclear protein binding to the SPRR1B promoter region. Based on in vivo footprinting and transient transfection data, we chose a 7152/ 796 bp promoter fragment encompassing the functional TRE sites (7141 TRE and 7111 TRE-like). As shown in Figure 6a , nuclear extracts isolated from HBE1 (lanes 1 and 2), BEAS-2B (lanes 3 and 4), and A549 (lanes 5 and 6) cells formed a DNA-protein complex that was enhanced signi®cantly after PMA treatment. However, A549 cells displayed a very weak basal level protein binding as compared to HBE1 and BEAS-2B cells. As shown in Figure 6b , incubation of BEAS-2B cell nuclear extracts with SPRR1B promoter forms a retarded complex (lane 1). The speci®city of the DNA-protein complex was demonstrated by selfcompetition with the unlabeled probe of SPRR1B promoter ( Figure 6b , lanes 2 and 3) and with the unlabeled consensus AP-1 oligonucleotide (Figure 6b , lanes 4 ± 6). Preincubation of nuclear extracts with an excess amount (25 ± 100-fold molar excess with respective labeled probe) of unlabeled SPRR1B promoter or with AP-1 signi®cantly blocked the DNA-protein complex formation. A similar type of gel shift pattern was observed with other cell nuclear extracts (data not shown).
We next characterized the composition of the DNAprotein complex binding at the SPRR1B promoter using antibodies speci®c for the individual members of the AP-1 family as described above. Band supershift pro®les of nuclear protein binding to the 7152/ 796 bp SPRR1B promoter in both untreated and PMA-treated BEAS-2B, HBE1, and A549 cells are shown in Figure 6c ± e. BEAS-2B cell nuclear extracts displayed prominent binding of JunD and Fra2 ( Figure  6c ). PMA signi®cantly enhanced complex formation with an increase in the binding of JunB and Fra1. Nuclear extracts from HBE1 cells displayed both JunD and Fra2 binding (Figure 6d, left panel) . However, Figure 4 The 7152 bp SPRR1B promoter activity in various normal and malignant cells. Cells were grown to 70 ± 80% con¯uency and then co-transfected with 1.0 mg of chimeric construct containing a 7152 to +12 bp 5'-¯anking region linked to a reporter CAT gene along with 1.0 mg of CMV-b-gal vector as described in Materials and methods. Cells used were as follows: Primary cultured tracheobronchial epithelial cells (PBE) and keratinocytes (HKRT); immortalized normal BE cell line, BEAS-2B; malignant cell lines, A549, A431, A172 and Caco2. Transient transfections were carried out using lipofectin as transfection agent according to manufacturer's recommendations. After overnight incubation, medium was replaced with fresh culture medium containing vehicle (open bars) or PMA (closed bars, 100 ng/ml for all cell lines; 5 ng/ml for PBE and HKRT) and CAT gene expression was analysed. The promoter activity was expressed as ng of CAT/b-gal units Figure 7 , overexpression of c-jun also enhanced SPRR1B promoter activity in A549 cells (bar 4) but less potently than fra1. These data indicate c-jun alone is insucient for inducing SPRR1B in malignant cells.
Overexpression of fra2 suppresses the SPRR1B promoter activity in normal BE cells
The data presented in Figure 6e indicates that Fra2 binds to SPRR1B promoter in A549 cells. Moreover, PMA enhances the binding of Fra1 at the SPRR1B promoter in HBE1 and BEAS-2B cells but not in A549 cells. We next analysed the role for Fra2 in SPRR1B promoter regulation. BEAS-2B cells were transiently transfected with 152-SPRR1B-CAT3 reporter along with the wild type pCMV-fra2 expression vector and CAT expression was analysed. As shown in Figure 8 , fra2 expression strongly inhibited basal level SPRR1B promoter activity in a dose dependent manner ( Figure  8a ). Furthermore, overexpression of fra2 strongly suppressed PMA-stimulated CAT expression driven by SPRR1B promoter (Figure 8b , bar 4) as compared to vector-transfected PMA-treated controls (Figure 8b , . Moreover, overexpression of fra2 suppressed cJun-enhanced SPRR1B promoter activity. As shown in Figure 8c , overexpression of c-jun alone signi®cantly enhanced SPRR1B promoter activity as compared to empty vector transfected controls (Figure 8c , compare bar 4 with bar 1). However, when cells were simultaneously co-transfected with fra2 and c-jun, fra2 strongly suppressed c-Jun-enhanced SPRR1B promoter activity (Figure 8c , compare bar 4 with bar 5). These results strongly suggest that Fra2 negatively regulates SPRR1B expression in BE cells.
Discussion
The development of bronchogenic cancer, like other cancers, is a multi-step process characterized by multiple but sequential morphological, molecular and genetic changes involved in cell growth and dierentiation (Fong et al., 1999) . Both in vivo and in vitro skin carcinogenesis models have indicated that alterations in the normal dierentiation process, in which cells become resistant to terminal dierentiation, are thought to be associated with neoplastic transformation of epidermal keratinocytes (Yuspa et al., 1996) . Similarly, neoplastic BE cells exhibit an altered response to terminal dierentiation marker gene expression indicating certain defect(s) in the normal dierentiation process (Jetten et al., 1992) . However, the precise mechanisms involved in this process are not clearly delineated due to a lack of a suitable in vivo model system. Recent studies indicate that SPRR1B overexpression in bronchial epithelium is a marker for early metaplastic changes, and that the loss of SPRR1B expression somehow disrupts or alters the corni®cation process leading to an irreversible malignant transformation (DeMuth et al., 1998; Lau et al., 2000) . Here we show the involvement of transcriptional regulatory mechanisms in dysregulation of SPRR1B expression in malignant BE cells. By in vivo footprint- Figure 6 Band shift pro®les of normal and malignant BE cells binding to the SPRR1B promoter. Band shift assays were performed essentially as described in Figure 5 except that 7152 to 786 bp SPRR1B promoter fragment (see Figure 3a) was used instead of the AP-1 oligonucleotide. (a) 32 P-end-labeled double-stranded SPRR1B promoter was incubated with 2 mg of nuclear extracts isolated from vehicle treated (7) and PMA-treated (+) cells. Lanes 1 and 2; extracts from HBE1; lanes 3 and 4, BEAS-2B; and lanes 5 and 6, A549 cells. (b) BEAS-2B cell nuclear extracts were preincubated either with unlabeled double-stranded SPRR1B promoter (0-, 25-, and 100-fold molar excess in lanes 1 ± 3 respectively) or with consensus AP-1 oligonucleotide (25-, 50-, and 100-fold molar excess in lanes 4 ± 6 respectively). (c ± e) represent supershift analysis of nuclear extracts isolated from vehicle treated (lanes 1 ± 7) and PMA-treated (8 ± 14) BEAS-2B (c), HBE1 (d) and A549 (e) cells ing and transient transfection, we demonstrate a strong correlation between DNA-protein interactions in vivo at the critical TREs and the reduced lower level SPRR1B expression in malignant BE cells. Furthermore, band shift analysis indicated a distinct pattern of AP-1 protein (Jun/Fos) binding to the SPRR1B promoter implying that either temporal expression and/or dierential activation of AP-1 proteins might play a regulatory role in dysregulation of SPRR1B expression when the cell becomes malignant. Further support for our data comes from the observations of Demuth et al. (1998) , who have demonstrated an apparent lack of rearrangement and/or deletion of genomic DNA of SPRR1B in various lung cancer cells. Another study reported that dierential expression of SPRR family members in normal keratinocytes and squamous cell carcinomas is not due to major genomic rearrangements or deletions thereby suggesting the possible involvement of transcriptional and/or posttranscriptional regulation (Lohman et al., 1997) . Together, these results indicate the involvement of transcriptional disruption mechanisms and the consequent dysregulation of SPRR1B expression in malignant cells.
It is well documented that neoplastic BE cells exhibit an altered response to PMA in which cells become resistant to PMA-induced terminal dierentiation. In several lung cancer cells, PMA either induces irreversible growth arrest or enhances dierentiation marker gene expression, indicating aberrations in PMAmediated signal transduction pathways that control the normal dierentiation process (Jetten et al., 1992) . AP-1 proteins are the main downstream regulators/ eectors of PMA that induce transcription of a variety of genes that are involved in cell growth and dierentiation. The Jun (c-Jun, JunB and JunD) proteins can either homodimerize or heterodimerize with the Fos proteins (c-Fos, Fos-B, Fra1 and Fra2), bZIP transcription factors (e.g., ATF/CREB, Maf/Nrf family members) as well as bHLH ZIP proteins (e.g., Myod and USF) resulting in dierential DNA binding and transactivation capacities to exert tissue-, stimulusand temporal-speci®c biologic eects (Karin et al., 1997) . During keratinocyte dierentiation AP-1 proteins are dierentially expressed in various compartments of the epidermis layer. For example, it was shown that c-Jun, JunB, JunD, fra1 and fra2 are expressed in the basal layer, JunD and fra1 are expressed in the spinous layers, and JunB and fra2 are expressed in the granular layer indicating distinct functions of members of the AP-1 family in regulating epidermal gene expression during dierentiation (Eckert and Welter, 1996) . Even though much data is accumulating about epidermal dierentiation, the exact roles of each member of the AP-1 family in the induction of airway squamous dierentiation are not clearly understood.
In the present study, we show that Jun/Fra1 dimers predominantly bind to the SPRR1B promoter in PMAstimulated BE cells indicating a prominent role for these AP-1 family members in the induction of airway squamous cell dierentiation. Intriguingly, the nature of the AP-1 complex bound to the TREs of SPRR1B is dierent in malignant BE cells. Jun/Fra2 dimers predominantly occupy the promoter indicating a suppressive role for Fra2 in regulation of SPRR1B expression in malignant BE cells. Indeed, overexpression of fra2 but not fra1 down regulates basal, c-jun and PMA-enhanced SPRR1B promoter activities in BEAS-2B cells (Figure 8 ). This implies that an alteration of the AP-1 composition might contribute to the dysregulation of dierentiation-speci®c gene expression in malignant BE cells. Consistent with this, a reduction in the basal level AP-1 transcriptional activity, in part due to a decrease in c-fos expression, was demonstrated in malignant BE cells (Lee et al., 1998) . Thus, dierential expression and/or activation of AP-1 family members might contribute to epithelial cell carcinogenesis.
The exact mechanism by which Fra1 and Fra2 dierentially regulate SPRR1B promoter activation in BE cells is not clearly understood. Unlike c-Fos and FosB, Fra1 and Fra2 lack transactivation potential but they form more stable heterodimeric complexes with the members of Jun family proteins (Karin et al., 1997) . These complexes then bind with high anity to the AP-1 binding site to dierentially (either negatively or positively) in¯uence the transcriptional activation of target gene expression (Abate et al., 1993) . For example, it was shown that c-Jun/Fra2 protein complexes suppress AP-1 transactivation induced by c-Jun homodimers (Suzuki et al., 1991) . Furthermore, Fra2 suppresses the AP-1 transcriptional activity in mouse keratinocytes that were induced to dierentiate by PMA (Rutberg et al., 1997) . In the present study, we showed that overexpression of fra2 down regulates both basal and PMA enhanced SPRR1B promoter activation in normal BE cells. Consistent with this observation, Fra2 binds to the SPRR1B promoter in A549 cells in which the SPRR1B expression is neither detectable nor inducible with PMA. This indicates that the AP-1 complex consisting of Fra2 suppresses transcriptional activation in malignant BE cells. Taken together, these results indicate that Fra2 acts as a strong suppressor of CE precursor gene expression. However, it is of interest to note that fra2 expression is highly abundant in both keratinizing (e.g., skin) and non-keratinizing (e.g., bladder, bronchi and small intestine) tissues which suggests that its expression is required for a more common physiological process in additional to dierentiation (Carrasco and Bravo, 1995) .
In contrast to fra2, overexpression of fra1 upregulates SPRR1B promoter activity in BEAS-2B and A549 cells. Moreover, band shift analysis indicates binding of Fra1 to the SPRR1B promoter region in BEAS-2B cells but not in A549 cells. It was shown that Fra1 forms complexes with Jun family members and dierentially regulates AP-1 activity depending on promoter and cellular context (Karin et al., 1997) . Several studies have demonstrated binding of Fra1 to the promoter region of involucrin (Welter et al., 1995) , loricrin (DiSepio et al., 1999) , SPRR1A (Sark et al., 1998) and SPRR3 (Fischer et al., 1999) indicating its role in CE precursor gene expression in keratinocytes. Recently, an inverse correlation was demonstrated between the composition of the AP-1 complex containing Fra1 and the malignant potential of cervicalcarcinoma cells (Soto et al., 2000) . In summary, these results indicate that Jun/Fra1 dimers might positively upregulate, while Jun/Fra2 dimers may down regulate dierentiation-speci®c gene expression.
It is not clear how binding of Fra1 and Fra2 proteins dierentially regulate the transcription of SPRR1B. However, one could argue that Fra2 might squelch the protein factors that positively regulate the Jun/Fra1 mediated SPRR1B promoter activation. Alternatively, Fra1 might compete with Fra2 to form heterodimers with Jun family members and nullify the suppressive eect of Fra2. It is also possible that Fra1 might compete with certain cellular factors that positively regulate Fra2 function. For example, ERK2-MAP kinase phosphorylates the c-terminal region of Fra2, thereby converting it from a transcriptionally inactive to active factor (Murakami et al., 1997) . Similarly, Fra1 is also phosphorylated by ERK2 (Gruda et al., 1994) . It seems that the elevated levels of Fra1 and/or decreased levels of phosphorylation of Fra2 lead to an increase in SPRR1B promoter activation. Recently, we have demonstrated that PMAstimulated SPRR1B promoter activation is not suppressed by dominant negative mutants of ERK1 and/or ERK2, indicating involvement of ERK-like kinase in regulation of SPRR1B expression (Vuong et al., 2000) .
Several studies have demonstrated that deacetylation of histones induces growth arrest, dierentiation and/ or apoptotic cell death in cultured tumor cells (Marks et al., 2000) . However, treatment of malignant A549 cells with histone deacetylase inhibitor TSA did not induce either basal or PMA-inducible SPRR1B expression (data not shown). Thus, acetylation/chromatin structure does not appear to be involved in the dysregulation of SPRR1B expression in malignant cells. In addition, epigenetic mechanisms such as DNA methylation also play a regulatory role in dierential gene expression during dierentiation and development (Momparler and Bovenzi, 2000) . Also, the loss of gene expression in human cancer cells has been correlated well with the methylation status of CpG islands of the promoter regions of dierentiation as well as several tumor suppressor genes (Momparler and Bovenzi, 2000) . The 7950 bp 5'-¯anking region of SPRR1B lacks a CpG island but contains three CpG sites located between 7450 to 7622 nt. Treatment of malignant A549 cells with demethylating agent 5-aza-2'-deoxycytidine did not induce either basal or TPAstimulated SPRR1B expression (data not shown). This suggests that dysregulation of SPRR1B expression in malignant BE cells is not due to an aberrant DNA methylation.
Intriguingly, both Fra1 and Fra2 bind to the consensus TRE site indicating that both are functionally active ( Figure 5 ). However, only Fra1 binds to the Loss of SPRR expression in lung tumor cells T Patterson et al SPRR1B promoter (Figure 6 ) further emphasizing the importance of cellular and promoter context,¯anking residues such as GT/CAC and ETS-like motifs, on the regulation of Fra1-dependent gene expression. Therefore, in addition to ubiquitous transcription factor(s), others, such as cell-speci®c transcription factor(s) may participate in regulation of SPRR1B expression. In fact, we noticed that overexpression of C/EBP proteins enhances, while GADD153 (which inhibits the action of C/EBPs) suppresses the SPRR1B promoter activation. This suggests the involvement of protein-factors other than AP-1 in SPRR1B promoter regulation (data not shown). Together, these results suggest that both the activation and proximal availability of Fra1 and Fra2 with other proteins such as Jun members and/or cell type-speci®c factors might be involved in regulation of SPRR1B expression in airway epithelial cells. Further studies are needed to determine cell-type speci®c signaling mechanisms as well as the factor(s), both cell type-speci®c and ubiquitous, and co-activator(s), that are required for dierentiation-speci®c expression of SPRR1B in BE cells to gain additional insights into the development of airway squamous metaplasia and bronchial carcinogenesis.
Materials and methods
Cell culture
Primary TBE cells were isolated from rhesus monkey and human tracheobronchial tissues and cultured as described previously (Reddy et al., 1995) . The immortalized normal human TBE cell lines, HBE1 and BEAS-2B sub clone S6, were obtained from Drs JF Lechner and J Yankaskas, respectively. These cell lines were maintained in a serum-free hormone-supplemented medium (Reddy et al., 1995) . Human primary epidermal keratinocytes were cultured as previously described (McClaren and Issero, 1994) . Other cell lines, A549 (adenocarcinoma), NCI-H520 (squamous cell carcinoma), H358 (bronchioloalveolar cell carcinoma), A431 (epidermoid carcinoma), H661 (lung large cell carcinoma), Caco-2 (colon adenocarcinoma), and A172 (glioblastoma) were obtained from the American Type Culture Collection. All cells were maintained in culture medium supplemented with 10% serum according to the supplier's data sheet.
Northern blot analysis
Cells were treated with either DMSO or PMA (100 ng/ml for cell lines, and 5 ng/ml for primary cultures) for the dierent time periods indicated. Total RNA (20 mg/lane) was separated on a 1.2% agarose gel and transblotted. Northern blot analysis was carried out using 32 P-labeled cDNAs of SPRR1B and 18S RNA as previously described (Vuong et al., 2000) .
Semi-quantitative RT ± PCR analysis
Total RNA (1.5 mg) was reverse transcribed into cDNA in a volume of 50 ml, containing 16PCR buer (50 mM KCl, 10 mM Tris-HCl, pH 8.3), 5 mM MgCl 2 , 1 mM dATP, dGTP, dCTP and dTTP, 125 ng oligo (dT) and 50 U of M-MLV reverse transcriptase (Life Technologies, MD, USA), at 458C for 15 min and 958C for 5 min. PCR ampli®cation was performed with an aliquot of cDNA (2 ml) in 16PCR buer containing 2 mM MgCl 2 , 400 mM dNTPs and 1.25 U Taq Polymerase (Promega Inc., WI, USA) in a total volume of 25 ml using 50 picomoles of primer pairs speci®c for human SPRR1B
(5'-ATACAGAGTATTCCTCTCTTCA-3'; 5'-TCTCTTCAGATGAATTCTGAGCAGCT-3' (Sark et al., 1998) or actb (5'-GAGAAAATC-TGGCACCACAAC-3'; 5'-TACCCCTCGTAGATGGGCAC-3') to yield 533 bp and 221 bp cDNA products, respectively. PCR was performed at 958C for 5 min followed by 35 (28 for Actb) cycles of 948C for 30 s, 538C for 1 min, and 728C for 1 min, with a ®nal 728C extension for 10 min. The number of cycles was chosen to ensure that the ampli®cation product did not reach a plateau level. The ampli®ed cDNA fragments were separated on a 1.2% agarose gel containing ethidium bromide, and quantitated using the Gel Doc 2000 System (Bio-Rad, CA, USA).
In vivo genomic footprinting
In vivo DMS footprinting was carried out as previously described (Reddy et al., 1995) . Brie¯y, cells were cultured to 70 ± 80% con¯uence followed by incubation with or without PMA for 12 h. Cells were subsequently treated with 0.1% dimethyl sulfate (DMS) for 2 min at room temperature in respective culture conditions without serum. Genomic DNA was then isolated using the phenol/chloroform extraction method. As an in vitro control, protein-free genomic DNA was prepared and treated with DMS for 20 ± 30 s at room temperature. Both in vivo and in vitro treated genomic DNA (3 mg) was subjected to piperidine treatment and the cleaved DNA fragments were ampli®ed by the ligation-mediated PCR method of genomic DNA sequencing (Mueller and Wold, 1989) . Ampli®ed DNA fragments were analysed on a 6% denaturing urea-polyacrylamide gel. Bands were detected following a 24 ± 48 h exposure on ®lm. DNA samples prepared from at least two separate batches of DMS-treated cells were analysed to demonstrate the reproducibility of data.
Transient transfections and reporter gene assays
Human 7152 to +12 bp SPRR1B promoter fused to chloroamphenicol acetyltransferase (CAT) gene has been described previously (Reddy et al., 1995) . DNA transfections were performed using a Fugene/lipofectin transfection reagent according to the manufacturer recommendations (Roche Biochemical Corporation). Cells were grown on 12 well plates at 70 ± 80% con¯uence and then transfected with 0.4 mg of promoter construct, 0.1 mg of CMV-b-galactosidase (b-gal) DNA, and 0.1 ± 0.8 mg of empty or expression plasmid vectors. After 18 ± 20 h post transfection, cells were treated with either DMSO or PMA (100 ng/ml) for 24 h. For primary cultured BE cells and epidermal keratinocytes, 5 ng/ml PMA was used. Cells were lysed and CAT expression was measured using an ELISA kit (Boehringer Mannheim Corp.). CAT expression of individual samples was normalized against b-gal units as described previously (Vuong et al., 2000) .
Electrophoretic mobility shift assay
Nuclear extracts from DMSO or PMA treated BE cells were prepared as previously described (Schreiber et al., 1989) . The binding was performed in a 20 ml reaction volume containing 25 mM HEPES, pH 7.9, 10% (v/v) glycerol, 30 mM NaCl, 0.1 mg/ml bovine serum albumin, 1 mM DTT, 5 mM MgCl 2 , 0.5 mM EDTA, 0.5 mg of salmon sperm DNA and 1 mg of poly (dI-dC). After incubation on ice for 10 min with 2 mg of nuclear extract, 0.1 ± 0.5 ng of Figure 3a) (20 000 c.p.m.) was added and incubated at room temperature for 30 min. The DNA-protein complexes were resolved on native 4% acrylamide gels containing 0.5 M Tris borate-EDTA buer containing 2% glycerol. For competition experiments, nuclear extracts were pre-incubated for 10 min with 25 ± 100-fold molar excess of unlabeled probe before adding labeled probe. For super shift analysis, nuclear extracts were mixed with 1 ± 2 mg of c-Jun (sc-45X), JunB (sc-46X), JunD (sc-74X), c-Fos (sc-7202X), Fra1 (sc-605x), and Fra2 (sc-604X) antibodies (all obtained from Santa Cruz Biotechnology, CA, USA) and incubated on ice for 1 ± 2 h prior to adding the labeled DNA probe.
Western blot analysis
BE cells were treated with or without PMA and total protein was extracted with keratin extraction buer (KEB: 20 mM Tris-HCl, pH 7.0, 0.6 M KCl, 1% Triton X-100, 1 mM PMSF). The protein concentration of the soluble fraction was measured using the DC-protein assay kit (Bio-Rad, CA, USA). An equal amount of protein was loaded into each well and subjected to electrophoresis on a 15% SDS ± PAGE gel. Western blot analysis was performed using polyclonal antibodies raised against the polypeptide corresponding to the ®rst 15 amino acids of the C-terminal region of human SPRR1B as previously described (Hu et al., 1998) .
